Comparing the Effectiveness of Tipiracil/Trifluridine Vs. Regorafenib in Elderly Metastatic Colon Cancer Patients
Author(s)
ABSTRACT WITHDRAWN
OBJECTIVES:
While the comparative effectiveness of Tipiracil/Trifluridine vs. Regorafenib in metastatic Colon Cancer (mCC) patients has been explored, the benefit-risk profile in elderly US patients is yet to be fully established. The study assesses the overall survival (OS) and incidence of known adverse events (AEs) associated with Tipiracil/Trifluridine vs. Regorafenib in elderly mCC patients in the US.METHODS:
Using the SEER-Medicare database, we identified mCC patients, aged 65 and older, who initiated either Tipiracil/Trifluridine or Regorafenib use between 1/1/2015 and 12/31/2019. We used chi-square and t-tests to assess differences in key baseline characteristics. Kaplan-Meier curves and Cox Proportional Hazard models were used to estimate the association between the use of Tipiracil/Trifluridine vs. Regorafenib and overall survival. We also quantified the incidence of commonly observed AEs for both treatments.RESULTS:
Overall, 418 mCC patients met our inclusion and exclusion criteria, of which 246 (59%) patients received Tipiracil/Trifluridine and 172 (41%) patients received Regorafenib. The population was mainly female (55%), with a mean age of 72.58 years. In total, 215 (51%) patients died during follow-up, with a median survival time of 227 days (95% CI: 139, 273) and 213 days (95% CI: 178, 280) for Tipiracil/Trifluridine and Regorafenib, respectively. However, the overall survival was not statistically significant after adjusting for age, race, sex, primary CC site, and Charlson Comorbidity Index (HR 1.097, 95% CI: 0.835, 1.44). Commonly observed AEs for Tipiracil/Trifluridine were anemia (n = 59 (24%)) and neutropenia (n = 26 (10.5%)) while for Regorafenib, it was hypertension (n = 61 (35%)) and fatigue (n = 22 (13%)).CONCLUSIONS:
Although our study was limited by sample size, the results were consistent with previous studies in other populations, which found similar survival rates when using Tipiracil/Trifluridine vs. Regorafenib. Incidence rates of AEs should be considered while making patient-centered treatment decisions.Conference/Value in Health Info
2023-05, ISPOR 2023, Boston, MA, USA
Value in Health, Volume 26, Issue 6, S2 (June 2023)
Code
RWD52
Topic
Clinical Outcomes, Real World Data & Information Systems, Study Approaches
Topic Subcategory
Comparative Effectiveness or Efficacy, Health & Insurance Records Systems
Disease
Drugs, Oncology